Early detection of pancreatic cancer in mouse models using a novel antibody, TAB004.
Pancreatic ductal adenocarcinoma (PDA) is the fourth-leading cause of cancer death in the United States with a 5-year overall survival rate of 8% for all stages combined. But this decreases to 3% for the majority of patients that present with stage IV PDA at time of diagnosis. The lack of distinct e...
Main Authors: | Shu-Ta Wu, Chandra D Williams, Priyanka A Grover, Laura J Moore, Pinku Mukherjee |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5819830?pdf=render |
Similar Items
-
Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma
by: Didier Dréau, et al.
Published: (2019-04-01) -
Combining the specific anti-MUC1 antibody TAB004 and LIP-MSA-IL-2 limits pancreatic cancer progression in immune competent murine models of pancreatic ductal adenocarcinoma
by: Dreau, Didier, et al.
Published: (2020) -
Overcoming Immunological Resistance Enhances the Efficacy of a Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma
by: Mahboubeh Yazdanifar, et al.
Published: (2019-09-01) -
Antibody-Guided In Vivo Imaging for Early Detection of Mammary Gland Tumors
by: Laura Jeffords Moore, et al.
Published: (2016-08-01) -
Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
by: Mari Iida, et al.
Published: (2013-10-01)